https://scholars.lib.ntu.edu.tw/handle/123456789/580199
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | Kang Y.-K. | en_US |
dc.contributor.author | Lin D.-Y. | en_US |
dc.contributor.author | Park J.-W. | en_US |
dc.contributor.author | Kudo M. | en_US |
dc.contributor.author | Qin S. | en_US |
dc.contributor.author | Chung H.-C. | en_US |
dc.contributor.author | Song X. | en_US |
dc.contributor.author | Xu J. | en_US |
dc.contributor.author | Poggi G. | en_US |
dc.contributor.author | Omata M. | en_US |
dc.contributor.author | Lowenthal S.P. | en_US |
dc.contributor.author | Lanzalone S. | en_US |
dc.contributor.author | Yang L. | en_US |
dc.contributor.author | Lechuga M.J. | en_US |
dc.contributor.author | Raymond E. | en_US |
dc.date.accessioned | 2021-09-01T01:53:43Z | - |
dc.date.available | 2021-09-01T01:53:43Z | - |
dc.date.issued | 2013 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84891915708&doi=10.1200%2fJCO.2012.45.8372&partnerID=40&md5=c3f9a6c07a37331bd8cf1ca4158b0742 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/580199 | - |
dc.description.abstract | Purpose: Open-label, phase III trial evaluating whether sunitinib was superior or equivalent to sorafenib in hepatocellular cancer. Patients and Methods: Patients were stratified and randomly assigned to receive sunitinib 37.5 mg once per day or sorafenib 400 mg twice per day. Primary end point was overall survival (OS). Results: Early trial termination occurred for futility and safety reasons. A total of 1,074 patients were randomly assigned to the study (sunitinib arm, n = 530; sorafenib arm, n = 544). For sunitinib and sorafenib, respectively, median OS was 7.9 versus 10.2 months (hazard ratio [HR], 1.30; one-sided P = .9990; two-sided P = .0014); median progression-free survival (PFS; 3.6 v 3.0 months; HR, 1.13; one-sided P = .8785; two-sided P = .2286) and time to progression (TTP; 4.1 v 3.8 months; HR, 1.13; one-sided P = .8312; two-sided P = .3082) were comparable. Median OS was similar among Asian (7.7 v 8.8 months; HR, 1.21; one-sided P = .9829) and hepatitis B-infected patients (7.6 v 8.0 months; HR, 1.10; one-sided P = .8286), but was shorter with sunitinib in hepatitis C-infected patients (9.2 v 17.6 months; HR, 1.52; one-sided P = .9835). Sunitinib was associated with more frequent and severe adverse events (AEs) than sorafenib. Common grade 3/4 AEs were thrombocytopenia (29.7%) and neutropenia (25.7%) for sunitinib; hand-foot syndrome (21.2%) for sorafenib. Discontinuations owing to AEs were similar (sunitinib, 13.3%; sorafenib, 12.7%). Conclusion: OS with sunitinib was not superior or equivalent but was significantly inferior to sorafenib. OS was comparable in Asian and hepatitis B-infected patients. OS was superior in hepatitis C-infected patients who received sorafenib. Sunitinib-treated patients reported more frequent and severe toxicity. ? 2013 by American Society of Clinical Oncology. | - |
dc.publisher | American Society of Clinical Oncology | - |
dc.relation.ispartof | Journal of Clinical Oncology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | aspartate aminotransferase; sorafenib; sunitinib; antineoplastic agent; carbanilamide derivative; indole derivative; nicotinamide; pyrrole derivative; sorafenib; sunitinib; abdominal distension; abdominal pain; adult; advanced cancer; aged; alopecia; anemia; Article; ascites; Asian; aspartate aminotransferase blood level; asthenia; cancer chemotherapy; cancer survival; cause of death; constipation; controlled study; decreased appetite; diarrhea; drug dose reduction; drug efficacy; drug safety; drug withdrawal; fatality; fatigue; female; fever; hand foot syndrome; hepatitis B; hepatitis C; human; hypertension; interactive voice response system; leukopenia; liver cell carcinoma; major clinical study; male; morning dosage; multiple cycle treatment; nausea; neutropenia; outcome assessment; overall survival; phase 3 clinical trial; priority journal; progression free survival; randomized controlled trial; rash; side effect; stomatitis; thrombocytopenia; vomiting; weight reduction; adolescent; analogs and derivatives; Carcinoma, Hepatocellular; clinical trial; disease free survival; Kaplan Meier method; Liver Neoplasms; middle aged; mortality; multicenter study; proportional hazards model; very elderly; young adult; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Young Adult | - |
dc.title | Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1200/JCO.2012.45.8372 | - |
dc.identifier.pmid | 24081937 | - |
dc.identifier.scopus | 2-s2.0-84891915708 | - |
dc.relation.pages | 4067-4075 | - |
dc.relation.journalvolume | 31 | - |
dc.relation.journalissue | 32 | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。